Overview
Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase (COX) enzymes, suppressing prostaglandin synthesis. While widely used as an antiplatelet and anti-inflammatory agent, aspirin carries significant implications for the gut microbiome and intestinal barrier integrity.
COX inhibition reduces protective prostaglandin production in the gastrointestinal mucosa, predisposing to NSAID enteropathy — a condition characterized by increased intestinal permeability, mucosal erosion, and shifts in microbial community composition ([1]). The resulting barrier damage can facilitate bacterial translocation and low-grade endotoxemia.
Aspirin use has also been examined in the context of neurological conditions. Epidemiological data link NSAID exposure patterns to altered microbiome profiles in Parkinson's disease cohorts ([2]), and aspirin appears alongside other pharmaceutical exposures (acetaminophen, amoxicillin) as a variable in autism-spectrum microbiome research ([3]).
Cross-References
- nutritional immunity — prostaglandin-mediated mucosal defense overlaps with innate barrier functions
- gut barrier — COX inhibition directly compromises barrier integrity
- parkinsons disease — NSAID-microbiome associations in neurodegeneration
- autism spectrum disorder — pharmaceutical exposure and microbiome disruption